How to Get Retatrutide in 2026: Every Route, Ranked by Risk

How to get retatrutide legally comes down to two doors, and both are narrow: a Lilly clinical trial, or Lilly's single-patient expanded access program, which only your doctor can request. As of September 2026, no approved version exists anywhere. Lilly's own line is that retatrutide "is legally available only to participants in Lilly's clinical trials" and "cannot be legally sold or marketed for human use," so every vial sold online comes from somebody other than Lilly.

That leaves a short list of legal options, each with a catch, and one very large gray market. The table below ranks all six, from lowest to highest risk.

Every route, side by side

Status and rules come from Lilly, ClinicalTrials.gov and the FDA. The approved-drug prices come from Lilly's and Novo Nordisk's self-pay price pages, as of September 2026.

How to get retatrutide through a clinical trial

Trials are the only route that puts Lilly's own retatrutide in your hands with doctors watching the whole time. They're also hard to get into right now.

On September 29, 2026, ClinicalTrials.gov listed 33 studies that give retatrutide (code name LY3437943) as a treatment. Only 2 were recruiting. One is a single-site Phase 2 study in Shenzhen, China, run by a company called Hudson Biotech rather than Lilly. The other is the one Lilly trial open to US patients: SYNERGY-Outcomes, a Phase 3 study aiming to enroll about 4,500 adults at 563 sites in 34 countries, 136 of them recruiting in the US.

SYNERGY-Outcomes is a liver trial. It wants people with fatty liver disease (MASLD) who have signs of scarring risk: liver fat of at least 8%, an ELF blood score of 9 to 10.8, and a liver stiffness reading of 10 to under 20 kPa, with a BMI of at least 25. Even if you qualify, you might not get retatrutide. The protocol has tirzepatide, retatrutide and placebo groups.

The big obesity trials are closed to new people. TRIUMPH-5, the head-to-head against tirzepatide that circulated on r/Retatrutide as "now recruiting," now shows "active, not recruiting," and so do TRIUMPH-6 through TRIUMPH-9. Lilly's initial TRIUMPH program had already enrolled more than 5,800 people.

To check for yourself, since this changes month to month:

1. Go to ClinicalTrials.gov and type retatrutide into the "Intervention/treatment" box.
2. Set the status filter to "Recruiting" and "Not yet recruiting."
3. Open each study and read the eligibility section before anything else.
4. Check Lilly's trial finder at trials.lilly.com for sites near you.
5. Call or email the site contact on the listing. Screening happens at the site.

Our read: with one recruiting US trial and it aimed at liver disease, a trial is a realistic route mainly for people who already know they have fatty liver with fibrosis risk. For everyone else, it's worth checking every month or two, because Lilly has more retatrutide studies underway and new ones get listed.

Expanded access and Right to Try

Lilly opened a pre-approval expanded access listing for retatrutide on ClinicalTrials.gov (NCT07629401) in June 2026. It's single-patient access, and every one of these has to be true:

1. You're 18 or older.
2. Your BMI is 35 or higher even after the highest available dose of an approved weight-loss drug that you took as directed and tolerated.
3. You have 2 or more serious or life-threatening obesity-related complications that you're already being treated for.
4. You can't join a retatrutide trial, because you don't meet its criteria or no enrolling site is reasonably close.
5. You and your doctor have discussed every standard option, including bariatric surgery.

The request has to come from your treating doctor, who contacts the Lilly Answers Center at 1-800-545-5979. The listing says patients and caregivers should go through their doctor rather than calling Lilly themselves, and that availability depends on geography, supply and an individual review. Lilly's general policy adds that it will only grant expanded access when doing so won't interfere with its trials.

Right to Try is the other federal route people ask about. It covers people with a life-threatening condition who have exhausted approved treatments and can't join a trial. The FDA's page is blunt about the limit: the law "does not require a sponsor to provide" the drug. We couldn't find any Lilly statement about Right to Try requests for retatrutide.

If you think you might qualify for either, bring the criteria above to your doctor. Our page on getting a retatrutide prescription covers what a doctor can and can't do in the meantime.

Why a doctor or compounding pharmacy can't supply it

Some telehealth sites and online clinics have advertised compounded retatrutide. No pharmacy can legally make it.

The FDA spelled out why in a warning letter dated September 9, 2025. Retatrutide has no USP monograph, isn't part of any FDA-approved drug, and isn't on the 503A bulk substances list, so regular compounding pharmacies can't use it. It isn't on the 503B list and isn't in any drug on the shortage list either, which rules out outsourcing facilities. The FDA's concerns page, current as of September 1, 2026, still says "retatrutide and cagrilintide cannot be used in compounding under federal law."

That letter went to a website selling compounded retatrutide, and it told the seller that its "compounded retatrutide drug products are unapproved new drugs and misbranded drugs." The agency says it has also warned telehealth companies for marketing retatrutide directly to consumers, and warned ingredient distributors for selling it to compounders.

So if a clinic offers you a retatrutide prescription, ask where the drug comes from. The honest answer can't be a licensed pharmacy.

What people actually buy online

Outside a trial, what people on r/Retatrutide describe using is a vial of powder bought from an online peptide seller. You add sterile water, then draw each dose with an insulin syringe. Threads asking where to find a reliable source keep coming up, and some posters call it gray-market use in plain words.

These vials aren't Lilly's product, and none of them are approved. Many carry labels saying they aren't meant for people or animals. The FDA doesn't accept that wording as a shield. In a warning letter dated August 24, 2026, to a seller listing retatrutide as "GLP-3 Reta," the agency said that "evidence obtained from your website establishes that your products are intended to be drugs for human use." Its GLP-1 page says the FDA has warned companies selling retatrutide and other GLP-1 type drugs with that kind of label while giving dosing instructions.

What can go wrong falls into four buckets:

1. Wrong contents. Lilly warns that illicit retatrutide "may contain unknown ingredients, harmful contaminants and impurities," and may have "too much or too little active ingredient, or the wrong ingredient entirely." That has already happened. Australia's regulator, the TGA, tested a vial sold as retatrutide after a user had uncontrollable vomiting and a torn esophagus, and found no retatrutide in it, just semaglutide at about 8 times the level in approved semaglutide products (alert published September 14, 2026).
2. Contamination and infection. In the August 2026 warning letter, the FDA notes that injectables bypass "some of the body's key defenses against toxins and microorganisms." In Victoria, Australia, health officials have linked 6 cases of acute liver injury since January 2026 to unapproved products labeled retatrutide, possibly from a contaminant (alert of June 19, 2026).
3. Dosing mistakes. Every dose depends on the labeled milligrams, the water you add and the syringe markings. Slip a decimal point and you've injected 10 times the dose. The FDA has received reports of adverse events, some needing a hospital stay, that may be tied to dosing errors with compounded semaglutide. That's class evidence, the closest we have.
4. No recourse. There's no recall system, no product label and nobody to report a bad batch to except the FDA's MedWatch.

If a vial turns cloudy or gets particles after mixing, which people on r/Retatrutide have posted about more than once, don't inject it. Get medical help now for severe belly pain that won't go away, vomiting that stops you keeping fluids down, yellowing skin or eyes with dark urine, redness and heat spreading from an injection site, fever, or swelling of the face or throat.

How people judge a seller before they buy

A seller's own claims tell you almost nothing. What people look for is proof tied to the exact vial they received.

The standard check is a batch-specific certificate from an independent lab. It needs to show four things: that the vial contains retatrutide (identity, usually by mass spectrometry), how pure it is (usually by HPLC), how many milligrams are actually in the vial, and, where offered, endotoxin or sterility results. Then check that the batch or lot number on the report matches the one printed on your vial. A report for a different batch doesn't cover yours. Our guide to retatrutide testing shows how to read one line by line.

Any one of these is a reason to walk away:

1. No batch report, or one that's missing the lab's name and a way to check it.
2. The same report used across many batches, or one that looks edited.
3. Claims of FDA approval, "pharmaceutical grade" or a "legal" product.
4. Lilly's name or logo, or anything sold as a pen. Lilly doesn't sell retatrutide at all.
5. A price far below other listings.
6. No working contact details or physical address.

Passing these checks lowers the risk. It doesn't make the product approved, legal or safe, and even a clean certificate says nothing about how the vial was handled after testing. If you're weighing this route anyway, our page on retatrutide for sale sets out what's listed and which checks apply to each vial, and the retatrutide vendors page covers how sellers compare on documentation.

What it costs, and what's approved today

In search results we checked on September 29, 2026, starting prices for a single 10 mg vial ran from about $30 to $70, and multi-vial packs worked out cheaper per vial. We haven't tested any of these, and price tells you nothing about contents.

Approved drugs in the same family are available now with a prescription. Anything we say about them is class evidence and doesn't transfer to retatrutide automatically. They are, though, what a doctor can actually prescribe:

Prices are as of September 2026: Zepbound and Foundayo from Lilly's LillyDirect pages, Wegovy from NovoCare Pharmacy, which also offers new patients $199 a month for the first 2 fills of the lowest doses. Insurance can bring these lower. Our retatrutide price page tracks what the vials cost and what Lilly has said about future pricing.

When retatrutide could reach pharmacies

Lilly said on July 23, 2026, that it's completing the manufacturing data package for a Biologics License Application (BLA) and plans to submit retatrutide for US approval in Q1 2027. It described its trial data as enough to support global submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea.

The FDA's review goals set the pace after that. For an original BLA, the standard goal is a decision within 10 months of the 60-day filing date, so about 12 months from submission. A priority review cuts that to 6 months after filing, about 8 months in all.

Our read: if Lilly files in Q1 2027 and nothing slips, a US decision would land somewhere between late 2027 (priority review) and early 2028 (standard review). Until then, a trial, expanded access, or an approved alternative is the legal route, and our where to buy retatrutide page will change the day a pharmacy can fill a prescription.